Filtered By:
Cancer: HER2
Drug: Taxotere
This page shows you your search results in order of date.
Order by Relevance | Date
Total 141 results found since Jan 2013.
Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer
CONCLUSION: A subset of patients (10%) receiving trastuzumab in the metastatic setting have achieved long-term survival beyond 20 years.PMID:37725049 | DOI:10.1093/oncolo/oyad258
Source: The Oncologist - September 19, 2023 Category: Cancer & Oncology Authors: Juan Luis Gomez Marti Azadeh Nasrazadani Ying Ding Daniel Normolle Adam M Brufsky Source Type: research
Tumor-derived exosomes RNA expression profiling identifies the prognosis, immune characteristics, and treatment in HR+/HER2-breast cancer
Aging (Albany NY). 2023 Aug 29;15. doi: 10.18632/aging.204986. Online ahead of print.ABSTRACTExosomes play crucial roles in intercellular communication and are involved in the onset and progression of various types of cancers, including breast cancer. However, the RNA composition of breast cancer-derived exosomes has not been comprehensively explored. We conducted microarray assays on exosomes isolated from breast cancer and healthy breast epithelial cells from three patients with hormone receptor (HR) +/ human epidermal growth factor receptor (HER2) - breast cancer and identified 817 differentially expressed genes (DEGs)....
Source: Aging - August 30, 2023 Category: Biomedical Science Authors: Qi Zhou Jing Wang Haiping Zhang Lu Sun Jingjing Liu Lingchao Meng Jingwu Li Source Type: research
Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence
CONCLUSION: This study reports real-world evidence showing similar pCR and EFS outcomes with treatment regimens with and without AC and raises awareness of possible overtreatment and long-term toxicity in some patients with HER2+ EBC with the use of AC.PMID:37479867 | DOI:10.1007/s40261-023-01291-6
Source: Clinical Breast Cancer - July 21, 2023 Category: Cancer & Oncology Authors: In ês Soares de Pinho Paulo Luz Lucy Alves Raquel Lopes-Br ás Vanessa Patel Miguel Esperan ça-Martins Lisa Gon çalves Ritas Freitas Diana Sim ão Maria Rold án Galnares Isabel Fernandes Silvia Artacho Criado Salvador Gamez Casado Jose Baena Ca ñada Source Type: research
Aminosteroid RM-581 Decreases Cell Proliferation of All Breast Cancer Molecular Subtypes, Alone and in Combination with Breast Cancer Treatments
This study demonstrates that RM-581 could be effective for the treatment of BC, especially TNBC.PMID:37445276 | DOI:10.3390/jcm12134241
Source: Clinical Genitourinary Cancer - July 14, 2023 Category: Cancer & Oncology Authors: Anna Burguin Jenny Roy Genevi ève Ouellette Ren é Maltais Juliette Bherer Caroline Diorio Donald Poirier Francine Durocher Source Type: research
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
CONCLUSIONS: Our findings support CXCR4 as a novel therapeutic target and a predictive biomarker for trastuzumab resistance in HER2+ breast cancer.PMID:37280713 | DOI:10.1186/s13058-023-01665-w
Source: Cell Research - June 6, 2023 Category: Cytology Authors: Shuying Liu Shelly M Xie Wenbin Liu Mihai Gagea Ariella B Hanker Nguyen Nguyen Akshara Singareeka Raghavendra Gloria Yang-Kolodji Fuliang Chu Sattva S Neelapu Adriano Marchese Samir Hanash Johann Zimmermann Carlos L Arteaga Debasish Tripathy Source Type: research
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study
CONCLUSIONS: This real-life study indicates that adding P to NCT-H enables higher pCR than NCT-H in HER2+ BC, while pCR was associated with lower relapse and better EFS time.PMID:37083566 | DOI:10.1080/0284186X.2023.2202330
Source: Acta Oncologica - April 21, 2023 Category: Cancer & Oncology Authors: Ahmet Bilici Omer Fatih Olmez Muhammed Ali Kaplan Berna Oksuzoglu Ahmet Sezer Nuri Karadurmus Erdem Cubukcu Mehmet Ali Nahit Sendur Sercan Aksoy Dilek Erdem Gul Basaran Burcu Cakar Abdallah T M Shbair Cagatay Arslan Ahmet Taner Sumbul Sema Sezgin Goksu Ib Source Type: research
